2014
Emerging Therapies for Glioblastoma
Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging Therapies for Glioblastoma. JAMA Neurology 2014, 71: 1437-1444. PMID: 25244650, DOI: 10.1001/jamaneurol.2014.1701.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood-Brain BarrierBrain NeoplasmsCell- and Tissue-Based TherapyDacarbazineGlioblastomaHumansImmunotherapyTemozolomideConceptsClinical trialsCommon primary malignant brain tumorPrimary malignant brain tumorCancer stemlike cellsInnovative clinical trialsBlood-brain barrierMalignant brain tumorsPatient-tailored treatmentNew radiotherapy techniquesHeterogeneous molecular featuresImmune system interactionsGrowth factor receptorTerms glioblastomaMedian survivalDisease courseImmune checkpointsTemozolomide chemotherapyMultimodal treatmentPatient enrollmentAggressive tumorsTreatment advancesBrain neoplasmsDrug exposureBrain microenvironmentMalignant gliomas
2011
Primary central nervous system lymphoma
Graber JJ, Omuro A. Primary central nervous system lymphoma. Current Opinion In Neurology 2011, 24: 633-640. PMID: 21968551, DOI: 10.1097/wco.0b013e32834cbdef.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaReduced-dose radiotherapyProgression-free survivalNervous system lymphomaNeurotoxicity ratesSystem lymphomaChemotherapy-only treatmentHigh-dose methotrexateStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyPhase II studyWorse cognitive outcomesChemotherapy regimenSalvage treatmentII studyOlder patientsOverall survivalBrain damageChemotherapyRadiotherapyAdditional neurotoxicityRoutine practiceNeuropsychological evaluation